- U.S. President Donald Trump is pushing the sector to negotiate for drug prices similar to those in Canada, which could impact whether companies choose to list their medicines here.

Canada-U.S. Trade Dominic LeBlanc, left, and Health Minister Marjorie Michel met on Feb. 23 with Innovative Medicines Canada and pharmaceutical firm representatives to discuss the U.S.’s most favoured nation approach, and the upcoming Canada-United States-Mexico Agreement review. The Hill Times photographs by Sam Garcia and Andrew Meade
- U.S. President Donald Trump is pushing the sector to negotiate for drug prices similar to those in Canada, which could impact whether companies choose to list their medicines here.
- U.S. President Donald Trump is pushing the sector to negotiate for drug prices similar to those in Canada, which could impact whether companies choose to list their medicines here.
























